Stockreport

Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentat...

Atossa Therapeutics, Inc.  (ATOS) 
Last atossa therapeutics, inc. earnings: 11/13 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.atossagenetics.com
PDF scientific presentation to spotlight potential in Duchenne carrier–associated pathologies SEATTLE Nov. 17, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS [Read more]